Medtronic's Dual Regulatory Win and $0.72 Payout Anchor a Busy Stretch of Portfolio Surgery
Published on 09/30/2026 at 18:50 | Editorial boerse-global.de
Medtronic is having a fortnight that touches nearly every corner of its business — from the electrophysiology lab to the shareholder register. Fresh clearances for two cardiac devices landed the same day the medtech giant confirmed its quarterly cash distribution, while a sweeping corporate overhaul continues to reshape what the company looks like on paper.
The board signed off on a dividend of $0.72 per common share for the second quarter of fiscal 2027. Investors of record as of September 25, 2026 will collect the payment on October 16, 2026.
Green Light on Both Sides of the Atlantic
Regulators handed Medtronic a pair of wins for its cardiology lineup. The U.S. Food and Drug Administration granted clearance, and European authorities awarded CE marking, for the Affera Prism-2 mapping software. In a separate European decision, the PulseSelect ProxBox adapter — which carries an integrated proximity indicator — also secured CE certification.
Prism-2 is built to generate three-dimensional maps of the heart's electrical activity during ablation procedures. It fuses magnetic and impedance-based tracking to give physicians a precise view of diagnostic catheters, allowing interventions to be performed with sharply reduced fluoroscopy exposure or none at all. Functional add-ons include beat-to-beat comparison and targeted tagging of stimulation sites.
The ProxBox adapter slots into the PulseSelect pulsed field ablation (PFA) platform. Before energy is delivered, it feeds the operator real-time, impedance-based feedback on how close the catheter sits to the target tissue. PulseSelect itself holds the distinction of being the first FDA-approved PFA catheter system and is now used clinically in more than 60 countries.
Should investors sell immediately? Or is it worth buying Medtronic?
Electrophysiology Is Doing the Heavy Lifting
Those approvals arrive against a backdrop of robust growth in cardiovascular care. Revenue in the Cardiovascular segment climbed 19.5% to $3.927 billion in the quarter ended July 31, with the Electrophysiology unit outpacing that at 29.5%.
Group-level results echo the momentum. Medtronic posted revenue of $9.76 billion for the first quarter of fiscal 2027, alongside adjusted earnings per share of $1.45 — a figure that came in ahead of prior expectations. Management now targets full-year adjusted EPS of $5.94 to $6.00, having raised its organic revenue growth outlook by 50 basis points to a range of 7.25% to 7.75%.
TD Cowen reiterated its buy rating and kept a $110 price target on the stock, pointing to sustained electrophysiology share gains and a favorable product mix in cardiac and vascular surgery as the engines behind the first-quarter surge.
MiniMed Split Moves Toward the Finish Line
Running parallel to the product news is a structural transformation centered on the separation of the diabetes unit, MiniMed. Roughly two weeks ago, Medtronic launched a formal exchange offer covering at least 80.1% of MiniMed shares. The groundwork was laid in March 2026, when MiniMed completed an IPO and Medtronic retained an ownership stake of about 90%.
Under the current offer, shareholders can swap Medtronic common stock into MiniMed shares at a 7% discount, capped at 4.5939 MiniMed shares per Medtronic share. Absent that ceiling, participants would receive roughly $107.53 in MiniMed stock for every $100 of Medtronic shares tendered. The maneuver is intended to sharpen capital allocation and give the balance sheet more breathing room.
Robots, Instruments and a $700 Million Bet
Medtronic has been equally aggressive on the surgical robotics front. About a month ago it struck a strategic partnership worth $700 million with Cornerstone Robotics, securing distribution rights for the Sentire surgical system in select markets outside the U.S. That platform earned CE marking in May 2026 for minimally invasive procedures spanning general surgery, gynecology, thoracic surgery and urology.
Medtronic at a turning point? This analysis reveals what investors need to know now.
On a related note, the company picked up FDA clearance more than a month ago for the LigaSure RAS Maryland tissue instrument, designed for use with its in-house Hugo system.
Where the Stock Stands
Shares changed hands at EUR 76.90 on the day of the regulatory news, a modest gain of 0.08%, and the market capitalization sits at EUR 100.01 billion. The stock has steadied after recent corporate actions, with the current quote near EUR 76.86.
Taken together — the dividend, the MiniMed separation, the robotics tie-up and a steady cadence of device approvals — Medtronic is assembling the pieces of a leaner, more focused operation. By expanding low-radiation mapping tools and sharper ablation platforms, the company is working to defend its footing in a cardiovascular therapy market that keeps growing.
Ad
Medtronic Stock: New Analysis - 30 September
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
